US Stock Markets

Medtronic launches Resolute Onyx™ Drug-Eluting Stent in India

Posted On : 2015-07-22 20:30:26( TIMEZONE : IST )

Medtronic launches Resolute Onyx™ Drug-Eluting Stent in India

Optimizing the treatment of coronary artery disease with a new foundation for future stent innovations, Medtronic plc. (NYSE: MDT) has announced launch of the Resolute Onyx™ Drug-Eluting Stent (DES) in India.

"With the new Core Wire technology, the Resolute Onyx DES sets a new standard for durable polymer DES. It is a revolution in stent technology that allows for improved deliverability in extremely tortuous arteries and enhanced conformability because of the flexible design, greater radiopacity and thinner struts", said Shamik Dasgupta Vice President Cardiac and Vascular Group, India Medtronic.

Built on the proven clinical performance and superior deliverability of the Resolute Integrity DES, the Resolute Onyx DES is the first stent to feature a new advancement called CoreWire Technology that allows it to have a denser core metal wrapped in a cobalt alloy outer layer. This new technology enables increased radiopacity (i.e., visibility during the procedure). Radiopacity is a very important feature and refers to a metal's ability in being opaque to one or another form of radiation, such as X-rays. Radiopaque objects block radiation rather than allow it to pass through making them visible on X-rays.

Resolute Onyx DES has thinner struts to help improve deliverability without compromising radial and longitudinal strength.

Resolute Onyx DES features PowerTrac™ technology, a new delivery system that was introduced earlier this year with the NC Euphora™ Noncompliant Balloon Dilatation Catheter. The result is a revolutionary new DES that provides superior deliverability which means it is exceptionally easy to navigate the stent through the tortuous and narrowed arterial segment that requires treatment. This makes it easier to address the needs of patients with complex cases who require better deliverability and tracking. This technology further reduces the force that is required to navigate the stent into the patient's anatomy thereby giving enhanced procedural confidence.

CoreWire Technology is the next new DES advancement after Continuous Sinusoid Technology (CST), which was previously introduced with the Resolute Integrity DES and the Integrity bare-metal stent. CST is a method of stent manufacturing that molds one single strand of wire into a sinusoidal wave enabling a continuous range of motion.

"Deliverability of a coronary stent has always been the mainstay in providing acute results during PTCA. Through an innovative Medtronic-developed process, Resolute Onyx™ DES is manufactured from a single strand of core wire into a sinusoidal wave form that provides a fluid range of motion without compromising the structural strength", said Managing Director & Vice President South Asia for India Medtronic, Mr. Milind Shah.

Resolute Onyx expands Medtronic's interventional cardiology portfolio of medical devices across Coronary, Renal Denervation and TAVI, and is the latest in a series of 12 new product introductions planned over the next two years.

In collaboration with leading clinicians, researchers and scientists, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers worldwide.

With ~ 61.5 Mn Coronary Heart Disease (CHD) patients in 2015, India becomes one of the largest contributors of CHD patients in the world. By 2020, India is expected to have the largest disease burden in the world and shall account for 1/3rd of the deaths. Approximately 9-10% of the CHD patients suffer from an acute coronary event, accounting for 4-5 Mn cases of Acute Coronary Syndrome (ACS) every year 1. Of this only ~ 1.6 Mn patients are treated with cardiac stents over the past 10 years. Cardiac stent therapy penetration in India is at 2.6% of the diseased population. 2

1 International Journal of Scientific and Research Publications, Volume 3, Issue 10, October 2013

2 National Interventional Council Registry 2015, Cardiology Society of India

Source : Equity Bulls